Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis

References

• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–8
   PubMed Web of Science ®Google Scholar
• Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents. Ann Oncol 1997; 8: 15–25
   PubMed Web of Science ®Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045–7
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–86
   PubMed Web of Science ®Google Scholar
• Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGF-A. Acta Oncol 2006; 45: 144–55
   PubMed Web of Science ®Google Scholar
• Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004; 24: 1759–63
   PubMed Web of Science ®Google Scholar
• Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006; 10: 588–612
   PubMed Web of Science ®Google Scholar
• Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis–drug-specific, dose-related effects. Acta Oncol 2003; 42: 294–303
   PubMed Web of Science ®Google Scholar
• Albertsson P, Lennernas B, Norrby K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 2008; 47: 293–300
   PubMed Web of Science ®Google Scholar
• Lennernas B, Albertsson P, Damber JE, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: A quantitative study. Apmis 2004; 112: 201–9
   PubMedGoogle Scholar
• Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. Apmis 2003; 111: 995–1003
   PubMedGoogle Scholar
• United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77:1–10.
   Web of Science ®Google Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219–44
   PubMedGoogle Scholar
• Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998; 55: 43–53
   PubMed Web of Science ®Google Scholar
• Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 2002; 4: 805–15
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104: 496–503
   PubMed Web of Science ®Google Scholar
• Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, et al. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001; 4: 163–73
   PubMedGoogle Scholar
• Steiner R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. Exs 1992; 61: 449–54
   PubMedGoogle Scholar
• Norrby K. Drug testing with angiogenesis models. Expert Opin Drug Discov 2008; 3: 1–17
   PubMedGoogle Scholar
• Folkman J. Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov 2007; 6: 273–86
   PubMed Web of Science ®Google Scholar
• Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998; 334: 1–8
   PubMed Web of Science ®Google Scholar
• Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000; 60: 6298–302
   PubMed Web of Science ®Google Scholar
• Focher F, Spadari S. Thymidine phosphorylase: A two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 2001; 1: 141–53
   PubMed Web of Science ®Google Scholar
• Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158–66
   PubMed Web of Science ®Google Scholar
• Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003; 63: 527–33
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338(6216)557–62
   PubMed Web of Science ®Google Scholar
• Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Perez-Perez MJ, et al. Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett 2002; 510: 83–8
   PubMedGoogle Scholar
• Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004; 10: 1843–52
   PubMed Web of Science ®Google Scholar
• Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4: 1331–6
   PubMed Web of Science ®Google Scholar
• Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res 1980; 40: 1885–9
   PubMedGoogle Scholar
• Howell SB, Wung WE, Taetle R, Hussain F, Romine JS. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 1981; 48: 1281–9
   PubMed Web of Science ®Google Scholar
• Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 2003; 42: 304–8
   PubMed Web of Science ®Google Scholar
• Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006; 98: 236–44
   PubMed Web of Science ®Google Scholar
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16:301–8.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 909–14
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007; 25: 4779–86
   PubMed Web of Science ®Google Scholar